Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide.
Abiraterone acetate (ABI) and enzalutamide (ENZ) are considered to be clinically relevant comparators among chemotherapy-naive patients with castration-resistant prostate cancer.
- Ref: Am J Epidemiol. 2020 Sep 18:kwaa190.
- Année de publication : 2020
- Auteurs : Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E.
- Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »